Our lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
IPF and PSC
While expressed at very low levels in normal tissues, αvβ6 and αvβ1 integrins are upregulated in the pulmonary tissues of IPF patients, and in the liver tissues of PSC patients. Both of these integrins serve as activators of TGF-ß, leading to increased collagen production and, ultimately, fibrosis in these tissues. By blocking the activation of TGF-ß by both αvβ6 and αvβ1, we believe bexotegrast (PLN-74809) may slow and potentially halt the progression of fibrosis in these patient populations.
- Bexotegrast (PLN-74809) has shown a favorable safety tolerability and pharmacokinetic profiles in a Phase 2a trial in patients with IPF
- Bexotegrast (PLN-74809) has shown a favorable safety tolerability and pharmacokinetic profiles in a Phase 2a trial in patients with PSC
- Stabilization of fibrosis as measured by QLF imaging was observed in the bexotegrast group while the placebo group showed progression of fibrosis at Weeks 12 and 24 in patients with IPF
- Good oral bioavailability and long half-life are promising for potential once-daily dosing
- Targeting of tissue-specific integrins is designed to maximize antifibrotic effect while avoiding systemic effects of TGF-β inhibition
- There are currently only two existing FDA-approved therapies for IPF; while both have shown modest slowing of disease progression, medical need remains high
- There are currently no FDA-approved therapies for PSC
- BEACON-IPF, a global Phase 2b trial in IPF, initiated
- INTEGRIS-PSC, a global Phase 2a trial in PSC, interim data reported
- Granted Orphan Drug Designation from FDA and EMA in IPF and PSC
- Granted Fast Track Designation from FDA in IPF and PSC